Literature DB >> 9561733

Vi-deficient and nonfimbriated mutants of Salmonella typhi agglutinate human blood type antigens and are hyperinvasive.

M Miyake1, L Zhao, T Ezaki, K Hirose, A Q Khan, Y Kawamura, R Shima, M Kamijo, T Masuzawa, Y Yanagihara.   

Abstract

We generated nonfimbriated mutants from both Vi-positive and -negative Salmonella typhi to analyze the role of type 1 fimbriae and Vi-antigen in bacterial invasion. A Vi-defective mutant of S. typhi GIFU 10007-3 was more invasive than the wild-type strain GIFU 10007. The wild-type strain expressing Vi-antigen did not agglutinate both Saccharomyces cerevisiae and human erythrocytes but Vi-defective mutants were able to agglutinate S. cerevisiae and human erythrocytes. Nonfimbriated mutants from Vi-negative GIFU 10007-3 lost the ability to adhere to S. cerevisiae but still could agglutinate human erythrocytes. The Vi-negative mutant increased secreted proteins and became 5-fold more invasive than the wild-type strain. Nonfimbriated Vi mutants became 50-120-fold more invasive than the wild-type GIFU 10007. To determine why nonfimbriated Vi mutants still agglutinate human red blood cells, we searched bacterial proteins that could bind human blood-type antigens. We finally identified a candidate 37 kDa outer membrane protein that recognized fucosyl-galactose, a structure common to blood type A, B and H antigens.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9561733     DOI: 10.1111/j.1574-6968.1998.tb12931.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  8 in total

Review 1.  Capsule-mediated immune evasion: a new hypothesis explaining aspects of typhoid fever pathogenesis.

Authors:  Manuela Raffatellu; Daniela Chessa; R Paul Wilson; Cagla Tükel; Mustafa Akçelik; Andreas J Bäumler
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

Review 2.  Typhoid fever: "you can't hit what you can't see".

Authors:  Tamding Wangdi; Sebastian E Winter; Andreas J Bäumler
Journal:  Gut Microbes       Date:  2012-03-01

3.  Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis.

Authors:  Christine Hale; Frances Bowe; Derek Pickard; Simon Clare; Jean-Francois Haeuw; Ultan Powers; Nathalie Menager; Pietro Mastroeni; Gordon Dougan
Journal:  Vaccine       Date:  2006-03-20       Impact factor: 3.641

4.  The Salmonella enterica serotype Typhi Vi capsular antigen is expressed after the bacterium enters the ileal mucosa.

Authors:  Quynh T Tran; Gabriel Gomez; Sangeeta Khare; Sara D Lawhon; Manuela Raffatellu; Andreas J Bäumler; Dharani Ajithdoss; Soma Dhavala; L Garry Adams
Journal:  Infect Immun       Date:  2009-11-09       Impact factor: 3.441

5.  The capsule-encoding viaB locus reduces intestinal inflammation by a Salmonella pathogenicity island 1-independent mechanism.

Authors:  Takeshi Haneda; Sebastian E Winter; Brian P Butler; R Paul Wilson; Cagla Tükel; Maria G Winter; Ivan Godinez; Renée M Tsolis; Andreas J Bäumler
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

6.  The capsule encoding the viaB locus reduces interleukin-17 expression and mucosal innate responses in the bovine intestinal mucosa during infection with Salmonella enterica serotype Typhi.

Authors:  Manuela Raffatellu; Renato L Santos; Daniela Chessa; R Paul Wilson; Sebastian E Winter; Carlos A Rossetti; Sara D Lawhon; Hiutung Chu; Tsang Lau; Charles L Bevins; L Garry Adams; Andreas J Bäumler
Journal:  Infect Immun       Date:  2007-06-25       Impact factor: 3.441

7.  Precise excision of the large pathogenicity island, SPI7, in Salmonella enterica serovar Typhi.

Authors:  Susan M Bueno; Carlos A Santiviago; Alejandro A Murillo; Juan A Fuentes; A Nicole Trombert; Paula I Rodas; Philip Youderian; Guido C Mora
Journal:  J Bacteriol       Date:  2004-05       Impact factor: 3.490

Review 8.  Yin and Yang of Biofilm Formation and Cyclic di-GMP Signaling of the Gastrointestinal Pathogen Salmonella enterica Serovar Typhimurium.

Authors:  Agaristi Lamprokostopoulou; Ute Römling
Journal:  J Innate Immun       Date:  2021-11-12       Impact factor: 7.111

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.